Abstract
Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 658-666 |
| Numero di pagine | 9 |
| Rivista | Journal of Hepatology |
| Volume | 59 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2013 |
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
-
SDG 3 Salute e benessere
Keywords
- BOC
- Boceprevir
- CHC
- Cost-effectiveness
- DT
- G1
- ICER
- NR
- PAR
- PI
- PegIFN
- RBV
- RR
- TVR
- Telaprevir
- boceprevir
- chronic hepatitis C
- dual therapy
- genotype 1
- incremental cost-effectiveness ratio
- non-response
- partial response
- pegylated interferon
- protease inhibitors
- relapse
- ribavirin
- telaprevir
Fingerprint
Entra nei temi di ricerca di 'Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver